Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia

Venetoclax, an FDA-approved Bcl-2 selective inhibitor for the treatment of chronic lymphocytic leukemia and acute myeloid leukemia (AML), is tolerated well in elderly patients with AML and has good overall response rates; however, resistance remains a concern. In this study, we show that targeting C...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Signal Transduct Target Ther
Glavni autori: Luedtke, Daniel A., Su, Yongwei, Ma, Jun, Li, Xinyu, Buck, Steven A., Edwards, Holly, Polin, Lisa, Kushner, Juiwanna, Dzinic, Sijana H., White, Kathryn, Lin, Hai, Taub, Jeffrey W., Ge, Yubin
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7042303/
https://ncbi.nlm.nih.gov/pubmed/32296028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-020-0112-3
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items